<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dextroamphetamine and amphetamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dextroamphetamine and amphetamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dextroamphetamine and amphetamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12369" href="/d/html/12369.html" rel="external">see "Dextroamphetamine and amphetamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13219" href="/d/html/13219.html" rel="external">see "Dextroamphetamine and amphetamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58227437"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">ADHD Stimulant Safety Alert</span>
<span class="collapsible-date">May 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA is requiring updates to the Boxed Warning and other sections in the prescribing information of prescription stimulants to ensure consistency across the class of medicines and address continuing concerns of misuse, abuse, addiction, and overdose. The current prescribing information for some prescription stimulants does not provide up-to-date warnings about the harms of misuse and abuse, and particularly that most individuals who misuse prescription stimulants get them from other family members or peers. The FDA is adding information that patients should never share prescription stimulants with anyone, and the Boxed Warning will describe the risks of misuse, abuse, addiction, and overdose consistently across all medicines in the class, as well as advise health care professionals to monitor patients closely for signs and symptoms of misuse, abuse, and addiction. Information on these risks is being required in several sections of the prescribing information, including Warnings and Precautions, Drug Abuse and Dependence, Overdosage, and Patient Counseling sections; updates to existing Medication Guides are also required to help educate patients and caregivers about these risks.</p>
<p style="text-indent:0em;">Further information can be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions&amp;token=2htBI%2BZJP9KguLNT5e%2FO5JB3a3lhB47gC48SVmgo9Z800H4ddHXFGN3vhQ%2BWdW5yurFpw9BeJ%2FM6gAUY1Tt1jyGUCu7UWgLKdtpLZMlcF4ajBtdi8HzFE4w2iTIacoZKOst31pB5%2B5utMl%2FdfB4GdprCpFXm3czU9pi4wB1ZjvM%3D&amp;TOPIC_ID=8723" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5708680"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dextroamphetamine/amphetamine has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine/amphetamine, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Before prescribing dextroamphetamine/amphetamine, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine/amphetamine treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F158728"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adderall;</li>
<li>Adderall XR;</li>
<li>Mydayis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911968"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Adderall XR;</li>
<li>APO-Amphetamine XR;</li>
<li>PMS-Amphetamines XR [DSC];</li>
<li>SANDOZ Amphetamine XR;</li>
<li>Teva-Amphetamine XR</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F158745"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Central Nervous System Stimulant</li></ul></div>
<div class="block doa drugH1Div" id="F158731"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i>
<b> Oral:</b> Initial: 5 mg once or twice daily; may increase daily dose based on response and tolerability in 5 to 10 mg increments at intervals ≥1 week up to a usual maximum of 40 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1','lexi-content-ref-11483144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1','lexi-content-ref-11483144'])">Ref</a></span>). Some experts recommend waiting up to 1 month before increasing dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1'])">Ref</a></span>). <b>Note</b>: Although doses &gt;40 mg/day will rarely be necessary, doses as high as 60 mg/day with close monitoring may be necessary for optimal response in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i>
<b>Oral:</b> Initial: 10 to 20 mg once daily in the morning; may increase daily dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1','lexi-content-ref-16871129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1','lexi-content-ref-16871129'])">Ref</a></span>). Some experts recommend waiting up to 1 month before increasing dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1'])">Ref</a></span>). Although doses &gt;40 mg/day will rarely be necessary, doses up to 60 mg/day may be necessary for optimal response in some patients, but the frequency and severity of adverse effects are increased with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344837','lexi-content-ref-Brent.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344837','lexi-content-ref-Brent.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Triple-bead extended</i>
<i>release</i>:<b> Oral:</b> Initial: 12.5 mg once daily in the morning; may increase daily dose based on response and tolerability in 12.5 mg increments at intervals ≥1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19012813','lexi-content-ref-29809075','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19012813','lexi-content-ref-29809075','lexi-content-ref-Manu.1'])">Ref</a></span>). Some experts recommend waiting up to 1 month before increasing dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1'])">Ref</a></span>). Maximum dose: 50 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="492e7374-6dbd-4720-be87-b0e1d7d4da48">Narcolepsy, daytime sleepiness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy, daytime sleepiness (alternative agent):</b>
<b>Oral:</b> Initial: 10 mg once daily in the morning; may increase daily dose based on response and tolerability in increments of 10 mg every week until optimal response is obtained; usual dosage range: 20 to 60 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25854650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25854650'])">Ref</a></span>). Some experts recommend initiating therapy with the IR formulation (FDA approved) and transitioning to extended release (off label) once the patient achieves a stable dose. Although the ER formulation is generally dosed once daily, some patients may require a second dose in the early afternoon (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Scammell.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Scammell.2019'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991837"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; the potential exists for elimination of amphetamine to be inhibited resulting in prolonged exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: There are no specific dosage adjustments provided in the manufacturer's labeling; dextroamphetamine is not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26926668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26926668'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Adderall XR:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; the potential exists for elimination of amphetamine to be inhibited resulting in prolonged exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>): 15 mg once daily in the morning.</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (GFR &lt;15 mL/minute/1.73 m<sup>2</sup>): Use is not recommended; dextroamphetamine is not dialyzable.</p>
<p style="text-indent:-2em;margin-left:2em;">Mydayis:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>): Maximum dose: 25 mg/day</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD (GFR &lt;15 mL/minute/1.73 m<sup>2</sup>): Use is not recommended; dextroamphetamine is not dialyzable</p></div>
<div class="block doha drugH1Div" id="F50989123"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F158732"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution and start at low end of dosage range.</p></div>
<div class="block dop drugH1Div" id="F158738"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13219" href="/d/html/13219.html" rel="external">see "Dextroamphetamine and amphetamine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Use lowest effective individualized dose; administer first dose as soon as awake; avoid late evening doses.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder: Note:</b> Extended-release products are not interchangeable on a mg-per-mg basis; use precaution to ensure appropriate product specific dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablets:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 3 to 5 years: Oral: Initial 2.5 mg once daily in the morning; increase daily dose by 2.5 mg at weekly intervals until optimal response is obtained; maximum daily dose: 40 mg/<b>day</b> administered in 1 to 2 divided doses per day; use intervals of 4 to 6 hours between doses. <b>Note:</b> Select patients may require daily dose to be given in 3 divided doses per day. Although FDA approved, current guidelines do not recommend dextroamphetamine/amphetamine use in children ≤5 years due to insufficient evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Oral: Initial: 5 mg once or twice daily; increase daily dose by 5 mg at weekly intervals until optimal response is obtained; usual maximum daily dose: 40 mg/<b>day</b> administered in 1 to 2 divided doses; use intervals of 4 to 6 hours between doses; some patients weighing &gt;50 kg may require and tolerate doses up to 60 mg/<b>day</b> in divided doses with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-19476419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-19476419'])">Ref</a></span>).<b> Note:</b> Some patients may require daily dose to be administered as 3 divided doses per day.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release capsules:</p>
<p style="text-indent:-2em;margin-left:6em;">Adderall XR:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial therapy: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Children 6 to 12 years: Oral: Initial: 5 to 10 mg once daily in the morning; increase daily dose by 5 mg or 10 mg at weekly intervals until optimal response is obtained; usual maximum daily dose: 30 mg/<b>day</b>; some patients weighing &gt;50 kg may require and tolerate doses up to 60 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-19476419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-19476419'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents 13 to 17 years: Oral: Initial: 10 mg once daily in the morning; may increase to 20 mg daily after 1 week if symptoms are not controlled; usual maximum daily dose: 20 mg<b>/day</b>; some patients weighing &gt;50 kg may require and tolerate doses up to 60 mg/<b>day</b> with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-19476419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-19476419'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Converting Adderall to Adderall XR: </i>Patients taking divided doses of immediate-release Adderall tablets may be switched to extended-release Adderall XR capsule using the same total daily dose (taken once daily); titrate dose at weekly intervals to achieve optimal response.</p>
<p style="text-indent:-2em;margin-left:6em;">Mydayis: <b>Note</b>: Do not substitute Mydayis for other amphetamine products on a mg-per-mg basis because of different amphetamine base compositions and differing pharmacokinetic profiles.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents 13 to 17 years: Oral: Initial: 12.5 mg once daily in the morning; may increase by 12.5 mg increments at weekly intervals; maximum daily dose: 25 mg<b>/day</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Immediate-release tablets: Oral: Initial: 5 mg daily; increase daily dose by 5 mg at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/<b>day</b> given in 1 to 3 divided doses per day; use intervals of 4 to 6 hours between doses</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Immediate-release tablets: Oral: Initial: 10 mg daily; increase daily dose by 10 mg at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/<b>day</b> given in 1 to 3 divided doses per day; use intervals of 4 to 6 hours between doses</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109175"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Children ≥3 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; elimination may be decreased with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">Adderall XR: Children ≥6 years and Adolescents ≤17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Initial dose: 5 mg once daily; maximum daily dose in children 6 to 12 years: 20 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use not recommended</p>
<p style="text-indent:-2em;margin-left:4em;">Mydayis: Adolescents 13 to 17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Reduce maximum daily dose to 12.5 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use not recommended</p></div>
<div class="block dohp drugH1Div" id="F51109176"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥3 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; elimination may be decreased with hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F56319344"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular events including <b>acute myocardial infarction</b> (MI), stroke, sudden cardiac death (SCD), <b>increased heart rate</b>, and <b>increased blood pressure</b> have been reported in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16182674','lexi-content-ref-16549404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16182674','lexi-content-ref-16549404'])">Ref</a></span>). Amphetamine and dextroamphetamine salts, similar to other CNS stimulants, have been associated with sudden cardiac death in children and adolescents with preexisting structural cardiac abnormalities. Available data in patients without congenital heart disease are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19528194','lexi-content-ref-23160939','lexi-content-ref-23382829','lexi-content-ref-22682429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19528194','lexi-content-ref-23160939','lexi-content-ref-23382829','lexi-content-ref-22682429'])">Ref</a></span>). A large retrospective cohort study showed an overall low incidence and risk of serious cardiovascular events in children and young adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22043968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22043968'])">Ref</a></span>); similarly, retrospective claims databases have not shown an increase in serious cardiovascular events (MI, sudden death, stroke) with stimulant use in young and middle-aged adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22161946','lexi-content-ref-23382829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22161946','lexi-content-ref-23382829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Dose-related; amphetamines increase the mean heart rate and systolic blood pressure by mediating noradrenergic and dopaminergic transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31133823','lexi-content-ref-20693523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31133823','lexi-content-ref-20693523'])">Ref</a></span>). This increase in heart rate and blood pressure can ultimately lead to cardiovascular events such as arrhythmias and/or MI.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; MI and SCD usually occur within hours (especially in cases of overdose), but arrhythmias usually occur with long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26998366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26998366'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20190905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20190905'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior structural heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20693523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20693523'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of SCD or other cardiovascular diseases (eg, MI, cardiac arrhythmias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20190905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20190905'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of QTc prolonging medications may increase the risk of arrhythmias</p>
<p style="text-indent:-2em;margin-left:6em;">• Strenuous exercise and dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20190905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20190905'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Growth suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Some studies have reported <b>growth retardation</b> in pediatric patients. Decreased height and weight changes have been described in children &lt;12 years receiving long-term treatment (ie, ≥3 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26544899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26544899'])">Ref</a></span>). Similarly, statistically significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed in pediatric patients (age range: 8 to 17 years) actively treated with stimulants (including, but not limited to methylphenidate) when compared to matched unmedicated controls; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched controls (38.3% vs 21.6%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26398435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26398435'])">Ref</a></span>). An association has been observed between cumulative stimulant exposure in childhood and decreased height velocity, decreased adult height, and increased weight in adulthood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421233'])">Ref</a></span>). In contrast, a longitudinal cohort-controlled trial reported no difference in peak height velocity and final adult height in subjects with attention-deficit/hyperactivity disorder and/or treated with stimulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25180281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25180281'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; possibly due to effects on CNS growth factors and hepatic growth factors and direct cartilage effects. Weight loss may result from appetite suppression, reduced food intake, increased activity, and metabolic shifts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18580502','lexi-content-ref-7580171','lexi-content-ref-9685453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18580502','lexi-content-ref-7580171','lexi-content-ref-9685453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Growth suppression in children: Delayed; appears to occur after months of active treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31473291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31473291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26516345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26516345'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment/cumulative exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421233','lexi-content-ref-31473291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421233','lexi-content-ref-31473291'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid autism disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26516345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26516345'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New-onset <b>psychosis </b>or <b>mania</b> and exacerbation of psychotic or manic symptoms (eg, delusional thinking, <b>auditory hallucination</b> and <b>visual hallucination</b>, mania) may occur with neurostimulant use in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338','lexi-content-ref-31681046','lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338','lexi-content-ref-31681046','lexi-content-ref-30893533'])">Ref</a></span>); symptoms resemble acute psychosis most commonly observed in schizophrenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31681046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31681046'])">Ref</a></span>). Amphetamine has also been associated with <b>aggressive behavior</b> or hostility in children; however, a causal relationship has not been established. A study of commercial insurance claims data from 221,846 patients (age: 13 to 25 years) prescribed amphetamines or methylphenidate reported a higher risk of psychosis with amphetamine products compared to methylphenidate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>). Studies in adults have suggested that the resolution of the psychotic episode may be incomplete without treatment and may take up to 6 months even if abstinence occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31681046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31681046'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Psychosis: Amphetamine stimulates the release of dopamine from presynaptic nerve endings and prevents its reuptake. This leads to an increased concentration of dopamine in the neuronal synapse, leading to glutamate dysregulation. Increased dopamine and glutamate dysregulation have been associated with the development of psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31681046','lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31681046','lexi-content-ref-30893533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed and varied; a study of commercial insurance claims data from 221,846 patients (age: 13 to 25 years) prescribed amphetamines or methylphenidate reported a mean time of 128 days (IQR: 48 to 333 days) from the time medication was dispensed to the first psychotic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>). In cases of overdose/intoxication, the onset of symptoms is usually acute and within hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting mood or psychotic disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of substance use/abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of mood and psychotic disorders (eg, major depression, bipolar disorder, and schizophrenia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26719291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26719291'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Young age (children, adolescents, and young adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26485338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26485338'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30893533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30893533'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome may occur when amphetamines are used in combination with drugs that affect the serotonergic neurotransmitter system in all ages. Early symptoms of serotonin syndrome include tachycardia, shivering, diarrhea, diaphoresis, muscle cramps, agitation, and increased body temperature; these symptoms are usually followed by hypertension, hyperthermia, hyperreflexia, delirium, tremors, and rigidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23343808','lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23343808','lexi-content-ref-25653508'])">Ref</a></span>). Prompt treatment is needed to minimize risk of adverse outcome, including death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23343808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23343808'])">Ref</a></span>). The incidence of serotonin syndrome from stimulants use is unknown, likely due to under reporting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Mechanism: Amphetamines increase serotonin release and inhibit reuptake, which can lead to dangerously high extracellular concentration of serotonin especially when used in combination with other drugs that also increase serotonin concentrations (eg, CYP2D6 inhibitors, serotonin reuptake inhibitors, serotonin-norepinephrine uptake inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31523132','lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31523132','lexi-content-ref-25653508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; symptoms usually begin within 24 hours of ingestion of the causative agent(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31523132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31523132'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic polymorphism: Poor CYP2D6 metabolizers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of CYP2D6 inhibitors; consult drug interactions database for more information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of serotonergic agents; consult drug interactions database for more information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25653508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25653508'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F158695"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are for the extended-release products in children, adolescents, and adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Systolic hypertension (adolescents: 7% to 35%; transient)<span class="lexi-table-link-container"> (<a aria-label="Systolic Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-systolic-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-systolic-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Systolic Hypertension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Systolic Hypertension" frame="border" id="lexi-content-systolic-hypertension" rules="all">
<caption style="text-align:center;">
<b>Dextroamphetamine and Amphetamine: Adverse Reaction: Systolic Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dextroamphetamine and Amphetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dextroamphetamine and Amphetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">17</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 or 20 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Isolated systolic blood pressure elevations ≥15 mmHg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: 11% to 14%), anorexia (22% to 36%), xerostomia (adolescents: 2% to 4%; adults: 23% to 35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (adults: 26%), insomnia (8% to 31%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations (adults: 2% to 4%), tachycardia (adults: 6%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 2</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Dextroamphetamine and Amphetamine: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Dextroamphetamine and Amphetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Dextroamphetamine and Amphetamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">191</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">64</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (adults: 2% to 4%), skin photosensitivity (adults: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (adults: 2% to 4%), weight loss (4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bruxism (adults: 2%), constipation (adults: 2% to 4%), diarrhea (adults: 3% to 6%), dyspepsia (children and adolescents: 2% to 4%), nausea (2% to 8%), teeth clenching (adults: ≤4%), tooth infection (adults: ≤4%), upper abdominal pain (adolescents: 4%), vomiting (children and adolescents: 2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (adults: 2% to 4%), erectile dysfunction (adults: 2% to 4%), urinary tract infection (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (children and adults: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (adults: 2% to 8%), anxiety (adults: 7% to 8%), asthenia (≤6%), depression (adults: 3%), dizziness (2% to 7%), drowsiness (adolescents and adults: 2% to 4%), emotional lability (2% to 9%), fatigue (≤6%), irritability (adolescents: 6%), jitteriness (adults: 2%), nervousness (children and adolescents: 6%), speech disturbance (adults: 2% to 4%), twitching (adults: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (adults: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (children and adolescents: 2% to 4%), fever (children: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Drug abuse, drug dependence</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Nissen 2006), increased blood pressure (Nissen 2006), peripheral vascular disease (Syed 2008), Raynaud phenomenon (Syed 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermatillomania, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis (Roberts 2006), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido, growth retardation (Poulton 2016), pituitary insufficiency (Abdalla 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ischemic bowel disease (intestinal), unpleasant taste</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azoospermia (Abdalla 2021), frequent erections, prolonged erection</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Fellner 1972), angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, auditory hallucination (Fluyau 2019), dysphoria, euphoria, exacerbation of Gilles de la Tourette syndrome, formication, mania (Cressman 2015), outbursts of anger, overstimulation, paresthesia, psychosis (Fluyau 2019), restlessness, talkativeness, tic disorder (including motor tics, vocal tics, and exacerbation of tics) (Lowe 1982), tremor, visual hallucination (Fluyau 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (Downes 2005), rhabdomyolysis (Santoro 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Non-cardiogenic pulmonary edema (Khan 2021), respiratory failure (Khan 2021)</p></div>
<div class="block coi drugH1Div" id="F158710"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, angioedema, anaphylaxis) to amphetamine or any component of the formulation; during or within 14 days following monoamine oxidase inhibitors (MAOIs) (including MAOIs such as linezolid or IV methylene blue).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F158692"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Peripheral vasculopathy effects have been observed at different times, at therapeutic doses, and in all age groups. Digital ulceration and/or soft tissue breakdown have been observed; further evaluation (eg, rheumatology) may be necessary in patients developing signs and symptoms of peripheral vasculopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disorders: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; elimination is reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bipolar disorder: May precipitate a mixed or manic episode in patients with bipolar illness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; elimination is reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Limited information exists regarding stimulant use in seizure disorder. Whereas patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk for seizure activity compared to the general population, a retrospective study using drug claims data showed that the use of stimulant medications was associated with a lower risk (Cortese 2013; Wiggs 2018). Manufacturers of some stimulants recommend discontinuing therapy if seizures occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AAN [Pringsheim 2019]; NICE 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use caution in this age group due to CNS stimulant adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Pediatric patients 12 years of age and younger experienced high plasma exposure to Mydayis and more adverse reactions, including insomnia and decreased appetite, compared to patients 13 years of age and older.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention-deficit disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Mydayis: Medication errors, including substitution and dispensing errors, may occur, leading to possible overdosage. Do not substitute Mydayis for other amphetamine products on a mg-per-mg basis because of different amphetamine base compositions and differing pharmacokinetic profiles.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Abrupt discontinuation following high doses for prolonged periods results in extreme fatigue, mental depression, and sleep EEG changes; may also result in other symptoms of withdrawal.</p></div>
<div class="block dosfc drugH1Div" id="F56460035"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Products contain equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate. For example, a 10 mg capsule or tablet contains dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, and amphetamine sulfate 2.5 mg.</p></div>
<div class="block foc drugH1Div" id="F158705"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall XR: 20 mg, 30 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall XR: 5 mg, 15 mg, 10 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mydayis: 37.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mydayis: 50 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mydayis: 25 mg, 12.5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 37.5 mg, 5 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall: 10 mg, 7.5 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall: 15 mg, 12.5 mg, 30 mg, 20 mg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall: 5 mg [scored; contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</p></div>
<div class="block geq drugH1Div" id="F158688"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5989309"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Adderall XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $8.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Amphet-Dextroamphet 3-Bead ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $12.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $12.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $12.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $12.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Amphetamine-Dextroamphet ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.72 - $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.72 - $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.72 - $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.72 - $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.72 - $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.67 - $7.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Mydayis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $13.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $13.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $13.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $13.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Adderall Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $12.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Amphetamine-Dextroamphetamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.17 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $0.28 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.19 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.62 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.23 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.23 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.32 - $2.06</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55330240"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall XR: 20 mg, 30 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adderall XR: 5 mg, 10 mg, 15 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg</p></div>
<div class="block csi drugH1Div" id="F158747"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block adm drugH1Div" id="F158707"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Administer Mydayis consistently either with food or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Administer in 1 to 3 divided doses per day with intervals of 4 to 6 hours between doses. To avoid insomnia, late evening doses should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Administer upon awakening; to avoid insomnia, afternoon doses should be avoided. Capsule may be swallowed whole or it may be opened and the contents sprinkled on applesauce. Applesauce should be consumed immediately without chewing. Do not divide the contents of the capsule. Do not take less than one capsule per day; a single capsule should not be divided.</p></div>
<div class="block admp drugH1Div" id="F52612521"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release tablet: Take on awakening; to avoid insomnia, last daily dose should be administered no less than 6 hours before retiring.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release capsule: Take on awakening. Avoid afternoon doses to prevent insomnia. Swallow capsule whole; do not chew or divide. May be administered with or without food; however, Mydayis should be taken in a consistent manner with regards to food. May open capsule and sprinkle contents on applesauce; consume applesauce/medication mixture immediately; do not store; do not chew sprinkled beads from capsule.</p></div>
<div class="block meg drugH1Div" id="F7874428"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Adderall: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F011522s045lbl.pdf%23page%3D15&amp;token=07cRj37hV7UAkPYptXPcz1dEMQWKe%2BphQmpfoJbNc2wdOPXWKe4rLH%2BoyHFKS4gxiawPHuuFY1EEfHWt6wKbXjQskOUdBG5HLAMJDVMpI01vVQSw8lhgGDoaoAP0oG7J&amp;TOPIC_ID=8723" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/011522s045lbl.pdf#page=15</a></p>
<p style="text-indent:-2em;margin-left:4em;">Adderall XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021303s038lbl.pdf%23page%3D22&amp;token=BicU0dt2aP%2B%2Bbn9cmlFz81JBFccZsv52rOEHsjz7W9wiUf5PptvzPYJLW48D1%2Byapw1OsNLpmq9yS%2BFll8aj1Pke0CzjrFWYi%2BmPr70R0uK1wMpzyNNe9%2FmnF%2FVqtIdg&amp;TOPIC_ID=8723" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021303s038lbl.pdf#page=22</a></p>
<p style="text-indent:-2em;margin-left:4em;">Mydayis: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022063s005lbl.pdf%23page%3D25&amp;token=SL6LFu2BHeOGsbybhkrvRfJphSoIpeKNNweCn3VDkRf%2FXWqknXZgSrNxzqb9qhI7qE2WPfTvilZbRjPatqJZxktiflEuYcxDBpnpRu0MemRlmnbryNyXJ5oveRfSSL5%2B&amp;TOPIC_ID=8723" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022063s005lbl.pdf#page=25</a></p></div>
<div class="block use drugH1Div" id="F158706"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD) as part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy, daytime sleepiness (immediate release only): </b> Treatment of narcolepsy.</p></div>
<div class="block mst drugH1Div" id="F158753"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Adderall may be confused with Adderall XR, Inderal</p>
<p style="text-indent:-2em;margin-left:4em;">Adderall XR may be confused with Adderall</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F158739"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F158697"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May decrease the excretion of Amphetamines. Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: May enhance the adverse/toxic effect of Amphetamines. Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a strong CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of CNS Stimulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May increase the absorption of Amphetamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Amphetamines may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: CNS Stimulants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Amphetamines may enhance the analgesic effect of Opioid Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Amphetamines may enhance the cardiotoxic effect of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors): Amphetamines may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities, including serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust dose as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Amphetamines may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Amphetamines. Tricyclic Antidepressants may potentiate the cardiovascular effects of Amphetamines. Amphetamines may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased cardiovascular effects when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F158723"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Amphetamine serum levels may be reduced if taken with acidic food, juices, or vitamin C. Management: Monitor response when taken concurrently.</p></div>
<div class="block pri drugH1Div" id="F158713"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;margin-left:0em;">Outcome information related to the use of amphetamine/dextroamphetamine in pregnant women with attention-deficit/hyperactivity disorder is limited (Ornoy 2018).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Data collection to monitor pregnancy outcomes following exposure to amphetamine/dextroamphetamine is ongoing. Health care providers are encouraged to enroll females exposed to amphetamine/dextroamphetamine during pregnancy in the National Pregnancy Registry for Psychostimulants (1-866-961-2388 and/or https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F15041845"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F158702"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiac evaluation (including medical or family history of sudden death or ventricular arrhythmia; ECG as indicated) should be completed at baseline and on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants. Monitor BP and heart rate (baseline, following dose increases and periodically during treatment); growth rate (height and weight) and appetite in children; weight in adults; signs of peripheral vasculopathy (eg, digital changes); sleep and behavioral changes; assess family history and evaluate for tics or Tourette syndrome prior to initiation of therapy; assess for new signs or worsening of tics or Tourette syndrome during treatment. Assess for risk of abuse (including a history of ethanol or drug abuse) prior to prescribing and signs of misuse, abuse, or substance use disorder throughout treatment (NICE 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Screen for bipolar disorder and risk factors for developing a manic episode prior to treatment; monitor for psychotic or manic symptoms (eg, delusional thinking, hallucinations, mania); monitor for development or worsening of aggressive behavior or hostility.</p></div>
<div class="block pha drugH1Div" id="F158691"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Amphetamines are noncatecholamine, sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.</p></div>
<div class="block phk drugH1Div" id="F158709"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The immediate-release tablets and ER capsules contain d-amphetamine and l-amphetamine salts in the ratio of 3:1.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Immediate-release tablet: 4 to 6 hours (Dopheide 2009); Adderall XR: 8 to 12 hours (Jain 2017); Mydayis: ≤16 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Extended release: Food does not affect absorption, but prolongs T<sub>max</sub> of Adderall XR by 2 to 3 hours and Mydayis by 4 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: d-amphetamine: 9 hours; l-amphetamine: 11 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 13 to 17 years: d-amphetamine: 11 hours; l-amphetamine: 13 to 14 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: d-amphetamine: 10 hours; l-amphetamine: 13 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic oxidation via cytochrome P450 to 4-hydroxyamphetamine (active) norephedrine (active), and alpha-hydroxy-amphetamine with both active metabolites subsequently oxidized to 4-hydroxy-norephedrine. Cytochrome P450 2D6 is primarily responsible for the formation of 4-hydroxy-amphetamine.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Immediate release: 3 hours; Adderall XR: 7 hours; Mydayis: 7 to 10 hours (children and adolescents 6 to 17 years), 8 hours (adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (highly dependent on urinary pH); excreted as unchanged amphetamine (30% to 40%, may range from ~1% in alkaline urine to ~75% in acidic urine), and derivatives of alpha-hydroxyamphetamine (50%)</p></div>
<div class="block phksp drugH1Div" id="F51221001"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Children eliminated amphetamine faster than adults. The elimination half-life is approximately 1 hour shorter for d-amphetamine and 2 hours shorter for l-amphetamine in children than in adults. However, children had higher systemic exposure to amphetamine (C<sub>max</sub> and AUC) than adults for a given dose of ER capsules, which was attributed to the higher dose administered to children on a mg/kg basis compared with adults. Upon dose normalization on a mg/kg basis, children showed 30% less systemic exposure compared with adults. Patients 6 to 12 years of age experienced higher systemic exposure (72% to 79% higher C<sub>max</sub> and 83% higher AUC), compared with adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Weight: Weight is the primary determinant of apparent differences in the pharmacokinetics of d- and l-amphetamine across the age range. Systemic exposure measured by AUC<sub>∞</sub> and C<sub>max</sub> decreased with increases in body weight, while apparent oral volume of distribution, apparent oral clearance, and elimination half-life increased with increases in body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58189575"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Biphetamine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Durophet</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Attent</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adderall | Dextroamphetamine mixed salts lannett</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adderall | Amphetamin salts | Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate | Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate | Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | Mixed amphetamine salts | Mydayis</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33959450">
<a name="33959450"></a>Abdalla TE, Kotsonis D, Best J, Ramasamy R, Wood E. Stimulant-induced pituitary failure and reversible azoospermia. <i>Cureus</i>. 2021;13(4):e14269. doi:10.7759/cureus.14269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/33959450/pubmed" id="33959450" target="_blank">33959450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adderall.2020.03">
<a name="Adderall.2020.03"></a>Adderall (dextroamphetamine/amphetamine) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AdderallXR.2020.08">
<a name="AdderallXR.2020.08"></a>Adderall XR (dextroamphetamine/amphetamine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD; http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343793">
<a name="21343793"></a>American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479. Methamphetamine Abuse in Women of Reproductive Age. <i>Obstet Gynecol.</i> 2011;117(3):751-755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/21343793/pubmed" id="21343793" target="_blank">21343793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20502173">
<a name="20502173"></a>Barnes BJ, Hollands JM. Drug-induced arrhythmias. <i>Crit Care Med</i>. 2010;38(6 suppl):S188-S197. doi:10.1097/CCM.0b013e3181de112a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/20502173/pubmed" id="20502173" target="_blank">20502173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7985607">
<a name="7985607"></a>Bashour TT. Acute myocardial infarction resulting from amphetamine abuse: a spasm-thrombus interplay? <i>Am Heart J</i>. 1994;128(6 Pt 1):1237-1239. doi:10.1016/0002-8703(94)90757-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/7985607/pubmed" id="7985607" target="_blank">7985607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16344837">
<a name="16344837"></a>Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ; SLI381.304 Study Group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.<i> CNS Spectr.</i> 2005;10(12)(suppl 20):16-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16344837/pubmed" id="16344837" target="_blank">16344837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brent.1">
<a name="Brent.1"></a>Brent D, Bukstein O, Solanto MV. Attention deficit hyperactivity disorder in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343808">
<a name="23343808"></a>Cooper BE, Sejnowski CA. Serotonin syndrome: recognition and treatment. <i>AACN Adv Crit Care</i>. 2013;24(1):15-20; quiz 21-2. doi:10.1097/NCI.0b013e31827eecc6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23343808/pubmed" id="23343808" target="_blank">23343808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22043968">
<a name="22043968"></a>Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. <i>N Engl J Med.</i> 2011;365(20):1896-1904. doi:10.1056/NEJMoa1110212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/22043968/pubmed" id="22043968" target="_blank">22043968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23294014">
<a name="23294014"></a>Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medication in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3): 227-246. doi:10.1111/jcpp.12036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23294014/pubmed" id="23294014" target="_blank">23294014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26485338">
<a name="26485338"></a>Cressman AM, Macdonald EM, Huang A, et al; Canadian Drug Safety and Effectiveness Research Network. Prescription stimulant use and hospitalization for psychosis or mania: A population-based study. <i>J Clin Psychopharmacol</i>. 2015;35(6):667-671. doi:10.1097/JCP.0000000000000406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26485338/pubmed" id="26485338" target="_blank">26485338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29378213">
<a name="29378213"></a>Dolan SB, Chen Z, Huang R, Gatch MB. "Ecstasy" to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA. <i>Neuropharmacology</i>. 2018;133:171-180. doi:10.1016/j.neuropharm.2018.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/29378213/pubmed" id="29378213" target="_blank">29378213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19476419">
<a name="19476419"></a>Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. <i>Pharmacotherapy</i>. 2009;29(6):656-679. doi:10.1592/phco.29.6.656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/19476419/pubmed" id="19476419" target="_blank">19476419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15953231">
<a name="15953231"></a>Downes MA, Whyte IM. Amphetamine-induced movement disorder. <i>Emerg Med Australas</i>. 2005;17(3):277-280. doi:10.1111/j.1742-6723.2005.00735.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/15953231/pubmed" id="15953231" target="_blank">15953231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926668">
<a name="26926668"></a>Ermer J, Corcoran M, Lasseter K, Marbury T, Yan B, Martin PT. A Single-dose, open-label study of the pharmacokinetics, safety, and tolerability of lisdexamfetamine dimesylate in individuals with normal and impaired renal function. <i>Ther Drug Monit</i>. 2016;38(4):546-555. doi:10.1097/FTD.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26926668/pubmed" id="26926668" target="_blank">26926668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18580502">
<a name="18580502"></a>Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(9):994-1009. doi:10.1097/CHI.ObO13e31817eOea7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/18580502/pubmed" id="18580502" target="_blank">18580502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4111106">
<a name="4111106"></a>Fellner MJ, Oppenheim M. Anaphylaxis following amphetamines. <i>Acta Derm Venereol</i>. 1972;52(1):49-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/4111106/pubmed" id="4111106" target="_blank">4111106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31133823">
<a name="31133823"></a>Ferrucci M, Limanaqi F, Ryskalin L, Biagioni F, Busceti CL, Fornai F. The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular formation. <i>Front Neuroanat</i>. 2019;13:48. doi:10.3389/fnana.2019.00048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/31133823/pubmed" id="31133823" target="_blank">31133823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16182674">
<a name="16182674"></a>Findling RL, Biederman J, Wilens TE, et al; SLI381.301 and .302 Study Groups. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. <i>J Pediatr</i>. 2005;147(3):348-354. doi:10.1016/j.jpeds.2005.03.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16182674/pubmed" id="16182674" target="_blank">16182674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31681046">
<a name="31681046"></a>Fluyau D, Mitra P, Lorthe K. Antipsychotics for amphetamine psychosis. A systematic review. <i>Front Psychiatry</i>. 2019;10:740. doi:10.3389/fpsyt.2019.00740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/31681046/pubmed" id="31681046" target="_blank">31681046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25492713">
<a name="25492713"></a>Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197. doi:10.2190/PM.48.3.d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/25492713/pubmed" id="25492713" target="_blank">25492713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16167346">
<a name="16167346"></a>Golub M, Costa L, Crofton K, et al. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine. <i>Birth Defects Res B Dev Reprod Toxicol. </i>2005;74(6):471-584. doi:10.1002/bdrb.20048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16167346/pubmed" id="16167346" target="_blank">16167346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20493783">
<a name="20493783"></a>Gonzalez-Heydrich J, Whitney J, Waber D, et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. <i>Epilepsy Behav</i>. 2010;18(3):229-237. doi:10.1016/j.yebeh.2010.02.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/20493783/pubmed" id="20493783" target="_blank">20493783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19528194">
<a name="19528194"></a>Gould MS, Walsh BT, Munfakh JL, et al. Sudden Death and Use of Stimulant Medications in Youths. <i>Am J Psychiatry.</i> 2009;166(9):992-1001. doi:10.1176/appi.ajp.2009.09040472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/19528194/pubmed" id="19528194" target="_blank">19528194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31421233">
<a name="31421233"></a>Greenhill LL, Swanson JM, Hechtman L, et al; MTA Cooperative Group. Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(8):978-989. doi:10.1016/j.jaac.2019.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/31421233/pubmed" id="31421233" target="_blank">31421233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22161946">
<a name="22161946"></a>Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. <i>JAMA</i>. 2011;306(24):2673-2683. doi:10.1001/jama.2011.1830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/22161946/pubmed" id="22161946" target="_blank">22161946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25180281">
<a name="25180281"></a>Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. <i>Pediatrics</i>. 2014;134(4):e935-944. doi:10.1542/peds.2014-0428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/25180281/pubmed" id="25180281" target="_blank">25180281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26398435">
<a name="26398435"></a>Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents.<i> J Pediatr Orthop</i>. 2017;37(5):348-354. doi:10.1097/BPO.0000000000000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26398435/pubmed" id="26398435" target="_blank">26398435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17380592">
<a name="17380592"></a>Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. <i>Br J Clin Pharmacol</i>. 2007;63(3):371-375. doi:10.1111/j.1365-2125.2006.02767.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/17380592/pubmed" id="17380592" target="_blank">17380592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women [published correction appears in <i>N Engl J Med</i>. 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28906602">
<a name="28906602"></a>Jain R, Jain S, Montano B. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord </i>2017; 19(5). doi:10.4088/PCC.17nr02153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/28906602/pubmed" id="28906602" target="_blank">28906602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34395145">
<a name="34395145"></a>Khan A, Talha B, Vyas V, Khan U, Rao S, Dhamoon A. Routine use of prescription adderall leading to non-cardiogenic pulmonary edema and respiratory failure. <i>Cureus</i>. 2021;13(7):e16371. doi:10.7759/cureus.16371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/34395145/pubmed" id="34395145" target="_blank">34395145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22430455">
<a name="22430455"></a>LaGasse LL, Derauf C, Smith LM, et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. <i>Pediatrics</i>. 2012;129(4):681-688. doi:10.1542/peds.2011-2209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/22430455/pubmed" id="22430455" target="_blank">22430455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30041133">
<a name="30041133"></a>Lecomte T, Dumais A, Dugré JR, Potvin S. The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. <i>Psychiatry Res</i>. 2018;268:189-192. doi:10.1016/j.psychres.2018.05.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/30041133/pubmed" id="30041133" target="_blank">30041133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29028437">
<a name="29028437"></a>Liu X, Carney PR, Bussing R, Segal R, Cottler LB, Winterstein AG. Stimulants do not increase the risk of seizure-related hospitalizations in children with epilepsy. <i>J Child Adolesc Psychopharmacol</i>. 2018;28(2):111-116. doi:10.1089/cap.2017.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/29028437/pubmed" id="29028437" target="_blank">29028437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23564273">
<a name="23564273"></a>López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. <i>Atten Defic Hyperact Disord</i>. 2013;5(3):249-265. doi:10.1007/s12402-013-0106-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23564273/pubmed" id="23564273" target="_blank">23564273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6950128">
<a name="6950128"></a>Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. <i>JAMA</i>. 1982;247(12):1729-1731.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/6950128/pubmed" id="6950128" target="_blank">6950128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7580171">
<a name="7580171"></a>Lurie S, O'Quinn A. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. <i>J Neuropsychiatry Clin Neurosci</i>. 1991;3(1):41-50. doi:10.1176/jnp.3.1.41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/7580171/pubmed" id="7580171" target="_blank">7580171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26719291">
<a name="26719291"></a>MacKenzie LE, Abidi S, Fisher HL, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. <i>Pediatrics</i>. 2016;137(1). doi:10.1542/peds.2015-2486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26719291/pubmed" id="26719291" target="_blank">26719291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10405498">
<a name="10405498"></a>Manos MJ, Short EJ, Findling RL. Differential Effectiveness of Methylphenidate and Adderall® in School-Age Youths With Attention-Deficit/Hyperactivity Disorder. <i>J Am Acad Child Adolesc Psychiatry.</i> 1999;38(7):813-819. doi:10.1097/00004583-199907000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/10405498/pubmed" id="10405498" target="_blank">10405498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160939">
<a name="23160939"></a>Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. <i>CNS Drugs</i>. 2013;27(1):15-30. doi:10.1007/s40263-012-0019-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23160939/pubmed" id="23160939" target="_blank">23160939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30893533">
<a name="30893533"></a>Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. <i>N Engl J Med</i>. 2019;380(12):1128-1138. doi:10.1056/NEJMoa1813751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/30893533/pubmed" id="30893533" target="_blank">30893533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mydayis.2020.08">
<a name="Mydayis.2020.08"></a>Mydayis (dextroamphetamine/amphetamine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2018">
<a name="NICE.2018"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. Published March 14, 2018. Accessed December 18, 2023. https://www.nice.org.uk/guidance/ng87
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549404">
<a name="16549404"></a>Nissen SE. ADHD drugs and cardiovascular risk. <i>N Engl J Med</i>. 2006;354(14):1445-1448. doi:10.1056/NEJMp068049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16549404/pubmed" id="16549404" target="_blank">16549404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29411149">
<a name="29411149"></a>Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. <i>Pharm Res</i>. 2018;35(3):46. doi:10.1007/s11095-017-2323-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/29411149/pubmed" id="29411149" target="_blank">29411149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10585981">
<a name="10585981"></a>Pelham WE, Gnagy EM, Chronis AM, et al. A Comparison of Morning-Only and Morning/Late Afternoon Adderall to Morning-Only, Twice-Daily, and Three Times-Daily Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder. <i>Pediatrics.</i> 1999;104(6):1300-1311. doi:10.1542/peds.104.6.1300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/10585981/pubmed" id="10585981" target="_blank">10585981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7): 894-921. doi:10.1097/chi.0b013e318054e724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10802980">
<a name="10802980"></a>Pliszka SR, Browne RG, Olvera RL, et al. A double-blind, placebo-controlled study of Adderall® and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry.</i> 2000;39(5):619-626. doi:10.1097/00004583-200005000-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/10802980/pubmed" id="10802980" target="_blank">10802980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26544899">
<a name="26544899"></a>Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99. doi:10.1097/YIC.0000000000000109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26544899/pubmed" id="26544899" target="_blank">26544899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26516345">
<a name="26516345"></a>Powell SG, Frydenberg M, Thomsen PH. The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patients. <i>Child Adolesc Psychiatry Ment Health</i>. 2015;9:50. doi:10.1186/s13034-015-0082-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26516345/pubmed" id="26516345" target="_blank">26516345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906. doi:10.1212/WNL.0000000000007466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16637807">
<a name="16637807"></a>Roberts H, Chamberlain A, Rennick G, McLean C, Gin D. Severe toxic epidermal necrolysis precipitated by amphetamine use. <i>Australas J Dermatol</i>. 2006;47(2):114-116. doi:10.1111/j.1440-0960.2006.00243.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16637807/pubmed" id="16637807" target="_blank">16637807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23276898">
<a name="23276898"></a>Santoro JD, Black JM, Hamm LL. A case of rhabdomyolysis in the presence of multiple risk factors and dextroamphetamine use. <i>Am J Med Sci</i>. 2013;345(6):494-496. doi:10.1097/MAJ.0b013e3182798040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23276898/pubmed" id="23276898" target="_blank">23276898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Scammell.2019">
<a name="Scammell.2019"></a>Scammell TE. Treatment of narcolepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed July 23, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23382829">
<a name="23382829"></a>Schelleman H, Bilker WB, Kimmel SE, et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. <i>PLoS One</i>. 2013;8(1):e52991. doi:10.1371/journal.pone.0052991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/23382829/pubmed" id="23382829" target="_blank">23382829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31523132">
<a name="31523132"></a>Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions. <i>Int J Tryptophan Res</i>. 2019;12:1178646919873925. doi:10.1177/1178646919873925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/31523132/pubmed" id="31523132" target="_blank">31523132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20190905">
<a name="20190905"></a>Sichilima T, Rieder MJ. Adderall and cardiovascular risk: A therapeutic dilemma. <i>Paediatr Child Health</i>. 2009;14(3):193-195. doi:10.1093/pch/14.3.193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/20190905/pubmed" id="20190905" target="_blank">20190905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20693523">
<a name="20693523"></a>Silva RR, Skimming JW, Muniz R. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. <i>Clin Pediatr (Phila)</i>. 2010;49(9):840-851. doi:10.1177/0009922810368289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/20693523/pubmed" id="20693523" target="_blank">20693523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26998366">
<a name="26998366"></a>Sinha A, Lewis O, Kumar R, Yeruva SL, Curry BH. Amphetamine abuse related acute myocardial infarction. <i>Case Rep Cardiol</i>. 2016;2016:7967851. doi:10.1155/2016/7967851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/26998366/pubmed" id="26998366" target="_blank">26998366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19012813">
<a name="19012813"></a>Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. <i>J Clin Psychiatry</i>. 2008;69(9):1437-1448. doi:10.4088/jcp.v69n0911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/19012813/pubmed" id="19012813" target="_blank">19012813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9685453">
<a name="9685453"></a>Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. <i>Pediatrics</i>. 1998;102(2 Pt 3):501-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/9685453/pubmed" id="9685453" target="_blank">9685453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11483144">
<a name="11483144"></a>Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.<i> Arch Gen Psychiatry</i>. 2001;58(8):775-782. doi:10.1001/archpsyc.58.8.775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/11483144/pubmed" id="11483144" target="_blank">11483144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22003063">
<a name="22003063"></a>Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2011;128(5):1007-1022. doi:10.1542/peds.2011-2654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/22003063/pubmed" id="22003063" target="_blank">22003063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18431096">
<a name="18431096"></a>Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. <i>J Clin Rheumatol</i>. 2008;14(1):30-33. doi:10.1097/RHU.0b013e3181639aaa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/18431096/pubmed" id="18431096" target="_blank">18431096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25854650">
<a name="25854650"></a>Thorpy MJ. Update on therapy for narcolepsy. <i>Curr Treat Options Neurol</i>. 2015;17(5):347. doi:10.1007/s11940-015-0347-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/25854650/pubmed" id="25854650" target="_blank">25854650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25653508">
<a name="25653508"></a>Vo K, Neafsey PJ, Lin CA. Concurrent use of amphetamine stimulants and antidepressants by undergraduate students. <i>Patient Prefer Adherence</i>. 2015;9:161-172. doi:10.2147/PPA.S74602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/25653508/pubmed" id="25653508" target="_blank">25653508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31473291">
<a name="31473291"></a>Waxmonsky JG, Pelham WE 3rd, Campa A, et al. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(12):1330-1341. doi:10.1016/j.jaac.2019.08.472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/31473291/pubmed" id="31473291" target="_blank">31473291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16871129">
<a name="16871129"></a>Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. <i>CNS Spectr</i>. 2006;11(8):625-639. doi:10.1017/s1092852900013687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/16871129/pubmed" id="16871129" target="_blank">16871129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22682429">
<a name="22682429"></a>Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. <i>BMC Cardiovasc Disord</i>. 2012;12:41. doi:10.1186/1471-2261-12-41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/22682429/pubmed" id="22682429" target="_blank">22682429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29809075">
<a name="29809075"></a>Wigal T, Brams M, Frick G, Yan B, Madhoo M. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. <i>Postgrad Med</i>. 2018;130(5):481-493. doi:10.1080/00325481.2018.1481712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/29809075/pubmed" id="29809075" target="_blank">29809075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29476037">
<a name="29476037"></a>Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. <i>Neurology</i>. 2018;90(13):e1104-e1110. doi:10.1212/WNL.0000000000005213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dextroamphetamine-and-amphetamine-drug-information/abstract-text/29476037/pubmed" id="29476037" target="_blank">29476037</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8723 Version 511.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
